Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy

Truini A, Biasiotta A, Di Stefano G, La Cesa S, Leone C, Cartoni C, Federico V, Petrucci MT, Cruccu G. CNS Neurol Disord Drug Targets. 2011;10(8):916-920.

Open-label, no control groupHumans

Design

Open-label, no control group

Subjects

20 patients with multiple myeloma and painful neuropathy from thalidomide and bortezomib

Dose used in the study

PEA 300 mg twice daily

Duration

2 months

What was measured

Pain; warmth thresholds; motor and sensory nerve conduction and laser-evoked potentials measured by blinded examiners

What the authors reported

Pain and all neurophysiological measures of myelinated A-alpha, A-beta and A-delta fibres improved (p < 0.05), though none returned to normal. Warmth thresholds (unmyelinated fibres) did not change.

Limits of this study

No control group; the authors note a placebo effect could explain the pain change. 20 patients. The objective nerve measures were assessed blind, which is the study's strength.

Source

PubMed 22229320 · doi:10.2174/187152711799219307

Entry checked against the abstract, supplied by Devlin on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.